Trial · NCT05762640
Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)
NCT05762640, Phase 2, Recruiting, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH). Trials, record NCT05762640. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05762640
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)
- NCT number
- NCT05762640
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Haemophagocytic Lymphohistiocytosis
- Interventions
- Ruxolitinib
- First posted
- 2023-03-09
- Last updated
- 2026-04-23
- Other registries' IDs
- eudract:2021-006878-23
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Survival until HSCT | Day 0 until HSCT, up to 8 weeks | |
| Secondary | Rate of patients achieving a complete response | Day 7, Day 14, Day 21, Day 28, Week 8, and Day-1 of the conditioning for HSCT | To evaluate the efficacy of Ruxolitinib |
| Secondary | Rate of patients achieving a partial response | Day 7, Day 14, Day 21, Day 28, Week 8, and Day-1 of the conditioning for HSCT | To evaluate the efficacy of Ruxolitinib |
| Secondary | Delay to obtain complete response | Day 0 up to Day-1 of the conditioning for HSCT | To evaluate the efficacy of Ruxolitinib |
| Secondary | Delay to obtain partial response | Day 0 up to Day-1 of the conditioning for HSCT | To evaluate the efficacy of Ruxolitinib |
| Secondary | Incidence of HLH reactivation | Day 0 up to Day-1 of the conditioning for HSCT | HLH reactivation after achieving complete or partial response. |
| Secondary | Timing of HLH reactivation | Day 0 up to Day-1 of the conditioning for HSCT | HLH reactivation after achieving complete or partial response. |
| Secondary | Occurrence of a viral infection de novo or worsening of pre-existing viral infection(s) | During Ruxolitinib treatment | To evaluate treatment tolerance |
| Secondary | Occurrence of adverse effects reported in the product information for Ruxolitinib | During Ruxolitinib treatment | To evaluate treatment tolerance |
| Secondary | Concentration of Ruxolitinib in blood | Blood sampling: Day 0, weekly until week 8 of treatment and at Day-8 prior to the conditioning for HSCT | to evaluate Pharmacokinetics |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05762640
GET https://conductscience.org/api/trials/v1/NCT05762640/registered